Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial

Novo Nordisk shares fall after ZEUS trial disappointment highlights 94% sales reliance

NOVO NORDISK : JP Morgan remains Neutral

What to Expect from Novo Nordisk’s Earnings

What to Expect from Novo Nordisk’s Earnings

Novo Nordisk's Stock Slumps After Failed Trial - Adding to the Company's Woes

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Novo Nordisk’s ziltivekimab misses endpoint in Phase III cardiovascular outcomes trial

Citi says the market's reaction in Novo Nordisk is somewhat overdone

Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients

Heart drug trial fails! Novo-Nordisk A/S plunges, deepening concerns over 'weight-loss drug dependency'

Heart drug trial fails! Novo-Nordisk A/S plunges, deepening concerns over 'weight-loss drug dependency'

Novo’s New Drug Fails in Closely Watched Heart, Stroke Study

Novo Nordisk drops as anti-inflammatory drug fails in late-stage trial

Ziltivekimab shows no MACE risk reduction in ZEUS trial for Novo Nordisk (NVO)

Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results

Novo Nordisk Stock Drops After Drug Fails in Cardiovascular Trial

Novo Nordisk Stock Tumbles on Late-Stage Trial Results